

Consolidated income statement, condensed

Income statement SEKm	3 months ending		12 months ending	
	31-Mar-21	31-Mar-20	31-Mar-21	31-Dec-20
Net sales	1,736	1,053	5,956	5,273
Cost of sales	-1,113	-684	-3,884	-3,455
Gross profit	623	369	2,072	1,818
Selling expenses	-263	-228	-909	-874
Administrative expenses	-69	-60	-282	-273
Research and Development	-8	-6	-26	-24
Other operating income and expenses	8	-1	34	25
Operating profit	291	74	889	672
Financial income and expenses	-4	-5	-12	-13
Profit after financial items	287	69	877	659
Tax	-61	-15	-185	-139
Profit for the period	226	54	692	520
<i>Attributable to:</i>				
<i>Equity holders of the Parent Company</i>	226	54	690	518
<i>Non-controlling interests</i>	0	0	2	2
Earnings per share (EPS) before dilution, SEK	2.01	0.48	6.16	4.63
Earnings per share (EPS) after dilution, SEK	2.00	0.48	6.14	4.61
Average number of shares after repurchases '000s	112,490	112,612	112,207	112,127
Number of shares at end of the period, '000	112,491	111,737	112,491	112,487
EBITA	326	106	1,022	802
Depreciations included in operating expenses				
- property, plant and equipment	-38	-35	-147	-144
- intangible non-current assets from acquisitions	-30	-27	-113	-110
- other intangible non-current assets	-5	-5	-20	-20

Statement of comprehensive income

SEKm	3 months ending		12 months ending	
	31-Mar-21	31-Mar-20	31-Mar-21	31-Dec-20
Profit for the period	226	54	692	520
Components that may be reclassified to profit for the period				
Foreign currency translation differences for the period	51	10	-41	-82
Components that will not be reclassified to profit for the period				
Revaluations of defined benefit pension plans	-	-	-5	-5
Tax attributable to items not to be reversed in profit or loss	-	-	1	1
Other comprehensive income	51	10	-45	-86
Total comprehensive income	277	64	647	434
<i>Attributable to:</i>				
<i>Equity holders of the Parent Company</i>	276	63	645	432
<i>Non-controlling interests</i>	1	1	2	2

Consolidated Balance sheet, Condensed

SEKm	31-Mar-21	31-Dec-20	31-Mar-21
Goodwill	1,113	1,100	1,025
Other intangible non-current assets	895	903	841
Property, plant and equipment	424	434	383
Financial non-current assets	23	20	25
Total non-current assets	2,455	2,457	2,274
Inventories	707	640	520
Current receivables	982	837	738
Cash and cash equivalents	364	216	90
Total current assets	2,053	1,693	1,348
Total assets	4,508	4,150	3,622
Total equity	2,162	1,890	1,509
Interest-bearing provisions	112	110	109
Non-interest-bearing provisions	154	161	134
Non-current interest-bearing liabilities	224	242	190
Non-current non-interest-bearing liabilities	1	1	1
Total non-current liabilities	491	514	434
Non-interest-bearing provisions	10	9	7
Current interest-bearing liabilities	576	564	893
Current non-interest-bearing liabilities	1,269	1,173	779
Total current liabilities	1,855	1,746	1,679
Total equity and liabilities	4,508	4,150	3,622

Statement of change in Group equity

Statement of change in Group equity, SEKm	1 Jan 21 – 31 Mar 21			1 Jan 20 – 31 Dec 20		
	Equity excl. non-controlling interests	Non-controlling interests	Total equity	Equity excl. non-controlling interests	Non-controlling interests	Total equity
Amount at beginning of period	1,882	8	1,890	1,467	9	1,476
Exercised and issued call options	-5	-	-5	58	-	58
Repurchase of treasury shares	-	-	-	-31	-	-31
Disposal of treasury shares	-	-	-	12	-	12
Dividend	-	-	-	-56	-3	-59
Non-controlling interests	-	0	0	-	0	0
Total comprehensive income	276	1	277	432	2	434
Amount at the end of the period	2,153	9	2,162	1,882	8	1,890

Cash flow statement, condensed

Cash flow statement, condensed SEKm	3 months ending		12 months ending	
	31-Mar-21	31-Mar-20	31-Mar-21	31-Dec-20
Profit after financial items	287	69	877	659
Adjustment for items not included in cash flow	103	68	315	280
Income tax paid	-36	-20	-113	-97
Changes in working capital	-170	-37	-25	108
Cash flow from operating activities	184	80	1,054	950
Net investments in non-current assets	-24	-21	-87	-84
Acquisitions and disposals	-6	-66	-285	-345
Cash flow from investing activities	-30	-87	-372	-429
Dividend paid to shareholders	-	-	-57	-57
Exercised and issued call options	-5	-	53	58
Repurchase and disposal of treasury shares	-	-31	12	-19
Other financing activities	-19	26	-399	-354
Cash flow from financing activities	-24	-5	-391	-372
Cash flow for the period	130	-12	291	149
Cash and cash equivalents at beginning of period	216	99	90	99
Exchange differences on cash and cash equivalents	18	3	-17	-32
Cash and cash equivalents at end of the period	364	90	364	216

Key financial indicators

	12 months up until				
	31-Mar-21	31-Dec-20	31-Mar-20	31-Dec-19	31-Dec-18
Net sales, SEKm	5,956	5,273	3,687	3,479	2,482
EBITA, SEKm	1,022	802	341	305	245
EBITA margin, %	17.2%	15.2%	9.2%	8.8%	9.9%
Profit growth, EBITA, %	200%	163%	32%	25%	5%
Return on working capital (P/WC), %	122%	103%	54%	51%	62%
Profit for the period, SEKm	692	520	161	142	129
Return on equity, %	39%	31%	11%	10%	16%
Financial net liabilities, SEKm	548	700	1,102	902	882
Financial net liabilities/EBITDA, multiple	0.5	0.7	2.3	2.1	3.3
Net debt/equity ratio, multiple	0.2	0.4	0.7	0.6	0.9
Equity ratio, %	48%	46%	42%	45%	35%
Average number of employees	1,045	1,004	927	903	620
Number of employees at end of the period	1,128	1,112	1,003	932	873

Key indicators include IFRS 16 from 2019, comparative figures have not been restated.

Key ratio definitions can be found [here](#).

Key financial indicators per share

	12 months up until				
	31-Mar-21	31-Dec-20	31-Mar-20	31-Dec-19	31-Dec-18
Earnings per share (EPS), SEK	6.16	4.63	1.43	1.28	1.29
Diluted EPS, SEK	6.14	4.61	1.43	1.28	1.29
Cash flow per share from operating activities, SEK	9.40	8.47	3.39	3.61	1.76
Shareholders' equity per share, SEK	19.14	16.73	13.34	13.07	9.08
Average number of shares after repurchases, '000s	112,207	112,127	112,431	111,083	100,458
Average number of shares adjusted for repurchases and dilution, '000s	112,670	112,652	112,751	111,297	100,458
Number of shares outstanding at end of the period, '000s	112,491	112,487	111,737	112,237	102,586

The number of shares from a historical perspective has been restated to take the bonus issue into account (i.e. the value of the subscription right) in the completed new share issue in 2019, as well as the share split (1:4) completed in May 2020 and has been used in all calculations of metrics for SEK per share. The conversion factor is 4.041.

Parent company

The Parent Company's net sales for the interim period amounted to SEK 14m (11) and profit after financial items amounted to SEK 1m (-1). At the end of the interim period, the Parent Company's net financial debt amounted to SEK 223m (726). The share capital at the end of the interim period was SEK 58m (58).

Income statement

SEKm	3 months ending		12 months ending	
	31-Mar-21	31-Mar-20	31-Mar-21	31-Dec-20
Net sales	14	11	44	41
Administrative expenses	-15	-13	-63	-61
Operating profit/loss	-1	-2	-19	-20
Interest income/expenses and similar items	2	1	10	9
Profit/loss after financial items	1	-1	-9	-11
Appropriations	-	-	135	135
Profit/loss before taxes	1	-1	126	124
Income tax expense	0	0	-26	-26
Profit/loss for the period	1	-1	100	98

Balance sheet

Balance sheet, SEKm	31-Mar-21	31-Dec-20	31-Mar-21
Intangible non-current assets	0	0	0
Tangible non-current assets	0	0	0
Non-current financial assets	2,017	2,100	2,146
Total non-current assets	2,017	2,100	2,146
Current receivables	359	343	126
Total current assets	359	343	126
Total assets	2,376	2,443	2,272
Equity	1,230	1,233	1,123
Untaxed reserves	96	96	56
Interest-bearing long-term liabilities	55	76	45
Non-interest-bearing long-term liabilities	1	1	2
Total long-term liabilities	56	77	47
Interest-bearing short-term liabilities	946	987	1,029
Non-interest-bearing short-term liabilities	48	50	17
Total short-term liabilities	994	1,037	1,046
Total equity and liabilities	2,376	2,443	2,272

Fair values on financial instruments

SEKm	31-Mar-21			31-Dec-20		
	Carrying amount	Level 2	Level 3	Carrying amount	Level 2	Level 3
Derivatives measured at fair value through profit or loss	0	0	–	0	0	–
Total financial assets at fair value per level	0	0	–	0	0	–
Derivatives measured at fair value through profit or loss	0	0	–	2	2	–
Contingent considerations	83	0	83	86	–	86
Total financial liabilities at fair value per level	83	0	83	88	2	86

The fair value and carrying amount are recognized in the balance sheet as shown in the table above.

For quoted securities, the fair value is determined on the basis of the asset's quoted price in an active market, level 1. As at the reporting date the Group had no items in this category. For currency contracts and embedded derivatives, the fair value is determined on the basis of observable market data, level 2. For contingent considerations, a cash-flow-based valuation is performed, which is not based on observable market data, level 3. For the Group's other financial assets and liabilities, fair value is estimated to be the same as the carrying amount.

Contingent considerations

SEKm	3 months ending		12 months ending	
	31-Mar-21	31-Mar-20	31-Mar-21	31-Dec-20
Carrying amount, opening balance	86	18	31	18
Acquisitions during the period	–	14	58	72
Consideration paid	-6	–	-6	–
Revaluation through profit or loss	–	–	1	1
Reversed through profit or loss	–	–	0	0
Interest expenses	1	–	1	0
Exchange differences	2	-1	-2	-5
Carrying amount, closing balance	83	31	83	86

Pledged assets and contingent liabilities in the Group

SEKm	31-Mar-21	31-Dec-20	31-Mar-20
Contingent liabilities	41	41	43

Reconciliation key ratios

Return on equity	Profit/loss after tax attributable to shareholders, as a percentage of shareholders' proportion of average equity.		
	31-Mar-21	31-Dec-20	31-Mar-20
Profit/loss for the period (roll 12 months)	692	520	161
Average equity	1,779	1,683	1,480
Return on equity	692/1,779= 39%	520/1,683=31%	161/1,480=11%

Return on working capital (P/WC)	EBITA in relation to average working capital.		
	31-Mar-21	31-Dec-20	31-Mar-20
EBITA	1,022	802	341
Average working capital (WC)	836	781	632
P/WC	1,022/836=122%	802/781=103%	341/632=54%

EBITA	Operating profit before amortization of intangible assets.		
	31-Mar-21	31-Dec-20	31-Mar-20
Operating profit (12 months rolling)	889	672	225
Amortization of intangible assets	133	130	116
EBITA	1,022	802	341

EBITA margin	Operating profit before amortization of intangible assets.		
	31-Mar-21	31-Dec-20	31-Mar-20
EBITA	1,022	802	341
Net sales	5,956	5,273	3,687
EBITA margin	1,022/5,956=17.2%	802/5,273=15.2%	341/3,687=9.2%

Definitions

EBITA	Operating profit before amortization of intangible assets.
EBITDA	Operating profit before depreciation and amortization
Equity per share	Shareholders' proportion of equity divided by the number of shares outstanding at the end of the reporting period
Cash flow per share	Cash flow from operating activities, divided by the average number of shares.
Net debt/equity ratio	Financial net liabilities in relation to shareholders' equity
Earnings per share (EPS)	Shareholders' proportion of profit/loss for the year in relation to the average number of shares outstanding
Profit growth EBITA	This year's EBITA decreased by last year's EBITA divided by last year's EBITA.
Financial net liabilities	Interest-bearing liabilities and interest-bearing provisions, less cash and cash equivalents.
Equity ratio	Equity as a percentage of total assets.

The key figures presented above are central in order to understand and evaluate AddLifes business and financial position. The key figures are presented in the "Key financial indicators" table and they are commented on in other parts of interim report.


The comparison figures for income and expense items relate to values for the period January–March 2020 and for balance sheet items as at 31 December 2020 if nothing else is stated.

The Share

The share capital at the end of the interim period amounted to SEK 58 million (58).

The number of repurchased own shares amounts to 2,007,149 Class B, corresponding to 1.8 percent of the total number of

shares and 1.3 percent of the votes. The average purchase price for shares held in treasury amounts to SEK 52.12 per share. The average number of treasury shares held during the interim period was 2,007,970 (2,332,428). The share price at 31 March 2021 was SEK 157.00 and the most recent price paid for the AddLife share on 27 April 2021 was SEK 213.00.



AddLife has three outstanding call option programmes totalling 2,574,000 Class B shares. Issued call options for treasury shares have resulted in a calculated dilution effect based on average share price for the interim period of approximately 0.7 percent (0.3). 880 options from the 2017/2021 program have been exercised during the interim period, corresponding to 3,696 B-shares. The remaining 55,323 options outstanding at the beginning of the interim period were repurchased at a price corresponding to market value.

Outstanding programmes	Number of warrants	Corresponding number of shares	Percentage of total number of shares	Exercise price	Exercise period
2020/2024	250,000	1,000,000	0.9%	98.40	19 Jun 2023 - 28 Feb 2024
2019/2023	215,000	860,000	0.8%	76.60	20 Jun 2022 - 28 Feb 2023
2018/2022	170,000	714,000	0.6%	56.00	16 Jun 2021 - 28 Feb 2022
Total	635,000	2,574,000			

On 31 March 2021, the number of shareholders amounted to 10,091, where of 56 percent are Swedish owners with respect to capital share. The 10 biggest shareholders controlled 55 percent of number of capital and 64 percent of votes.

Shareholders 2021-03-31	Class A-shares	Class B-shares	Share in %	
			of capital	of votes
Roosgruppen AB	2,156,572	3,893,759	5.28	16.32
Tom Hedelius	2,066,572	23,140	1.83	13.26
Verdipapirfond Odin	0	10,562,084	9.22	6.77
SEB Fonder	0	10,107,137	8.83	6.48
NTC Fidelity Funds Northern Trust	0	8,475,535	7.40	5.43
Swedbank Fonder	0	7,938,201	6.93	5.09
State Street Bank & Trust Company	0	7,263,316	6.34	4.65
J.P. Morgan Chase & Co	0	4,480,196	3.91	2.87
Handelsbanken fonder	0	2,813,121	2.46	1.80
Sandrew AB	0	2,800,000	2.45	1.79
Total the 10 biggest shareholders	4,223,144	58,356,489	54.65	64.46
Other shareholders	391,992	49,519,518	43.60	34.25
Total outstanding shares	4,615,136	107,876,007	98.25	98.71
Repurchased own shares Class B	-	2,007,149	1.75	1.29
Total registered shares	4,615,136	109,883,156	100.00	100.00

Source: Euroclear

Accounting policies

This interim report was prepared in accordance with IFRS and IAS 34 Interim Financial Reporting. Information in accordance with IAS 34.16A exist, except in the financial statements and the related notes also in other parts of the year end report. The interim report for the parent company was prepared in accordance with the Swedish Annual Accounts Act (1995:1554) and the Securities Market Act (2007:528) in compliance with recommendation RFR 2 Accounting for Legal Entities of the Swedish Financial Reporting Board. The accounting policies and basis for calculations applied in the 2020 annual report for AddLife AB were also used in the interim report. The amendments to IFRSs applicable from 1 January, 2021 have no effects to AddLife's financial reports for the interim period ended 31 March, 2021.

Alternative performance measures

AddLife presents certain financial measures in the interim report that are not defined according to IFRS. The Company believes that these measures provide valuable supplemental information to investors and the Company's management as they allow for evaluation of trends and the Company's performance. Since all companies do not calculate financial measures in the same way these are not always comparable to measures used by other companies. These financial measures should therefore not be considered as a replacement for measurements as defined under IFRS. This report provides information in greater detail regarding definitions of financial performance measures.

Transactions with related parties

No transactions with related parties that materially affected the Group's financial position and earnings took place during the interim period.

Events after the end of the interim period

On 7 April 2021, AddLife acquired all shares in Vision Ophthalmology Group GmbH (VOG), a leading European distributor and manufacturer in ophthalmology (eye surgery), with operations in Switzerland, Germany, the UK and Poland. VOG has a turnover of approximately EUR 70m and has 190 employees. For more information on the acquisition of VOG,

see [Acquisitions](#).

On 12 April 2021, AddLife signed an agreement to acquire all the shares of Healthcare 21 Group, HC21, a leading independent Life Science distributor with operations in Ireland and the UK. HC 21 has sales of approximately EUR 171m and around 450 employees. For more information on the acquisition of HC21, see [Acquisitions](#).

In connection with the acquisitions, additional credit facilities of SEK 2 250m were obtained from Handelsbanken. The credit agreement is for 12 months with an option to extend for up to an additional 24 months.

Two new issues of class B shares were carried out in conjunction with the two acquisitions. The newly issued shares have been used to pay for the acquisitions, in accordance with the mandate given to the Board of Directors at the Annual General Meeting in May 2020. The first issue was carried out on 7 April 2021 and included 3,862,216 class B shares. The first share issue increased AddLife's share capital by SEK 1,966,870.07. The second issue was carried out on 12 April 2021 and included 4,089,742 class B shares. As a result of the second share issue, AddLife's share capital was increased by SEK 2,082,739.85. After the two new issues, the share capital amounts to SEK 62,358,949.47. The total number of shares amounts to 122,450,250, with the number of class A shares unchanged at 4,615,136, while the number of class B shares increased from 109,883,156 to 117,835,114. Shares held in treasury have decreased from 2,007,149 to 507,149 class B shares after 1,500,000 class B shares were used as part of the payment for the shares in Vision Ophthalmology Group.

No other events of significance to the Group occurred after the end of the interim period.

Risks and uncertainties

AddLife's earnings and financial position, as well as its strategic position, are affected by various internal factors within AddLife's control and various external factors over which AddLife has limited influence. AddLife's most significant external risks are the state of the economy and market trends combined with public sector contracts and policy decisions, as well as competition. The risks and uncertainties are the same as in previous periods. For more information, see the section "Risks and uncertainties" in the administration report, in AddLife's annual report 2020. The Parent Company is indirectly affected by the above risks and uncertainties through its function in the Group.

Conference call

Investors, analysts and the media are invited to a conference call where CEO Kristina Willgård and CFO Martin Almgren will present the interim report. The presentation will be held in English and takes about 20 minutes, after which there will be an opportunity to ask questions. It will be recorded and made available online. If this is your first time using Teams, you will be asked to download an app.

The teleconference will be at 10:00 a.m. on 28 April 2021

If you wish to participate via teleconference, [please follow this link](#)>>

Or call in (only sound) +46 8 505 376 58 Conferens-ID: 321 695 644#

The presentation is also available on [AddLife YouTube](#) >>

Financial calendar

- The Annual General Meeting (AGM) of AddLife AB (publ) will be held on 5 May 2021, Stockholm
- The interim report for 1 January - 30 June 2021 will be published on 15 July 2021
- The interim report for 1 January - 30 September 2021 will be published on 22 October 2021
- The year-end report for 1 January - 31 December 2021 will be published on 3 February 2022

For further information, please contact:

Kristina Willgård, President and CEO, +46 70 510 12 23

Martin Almgren, CFO, +46 70 228 15 45

This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 7:45 a.m. CET on 28 April, 2021.

AddLife AB (publ), Box 3145, Brunkebergstorg 5, SE-103 62 Stockholm. info@add.life, www.add.life, org.nr. 556995-8126